Pharmacological prevention and treatment of vascular dementia: approaches and perspectives
- PMID:22796225
- DOI: 10.1016/j.exger.2012.07.002
Pharmacological prevention and treatment of vascular dementia: approaches and perspectives
Abstract
Vascular dementia (VaD) is a common dementing illness. There are no pharmacological agents with a regulatory approval for its treatment or prevention. Review of published clinical trial reports indicates that early treatment of hypertension, a risk factor for stroke, reduces VaD risk and slows progression. However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression. Pharmacological agents for treatment of Alzheimer's dementia (AD) such as memantine or acetylcholinesterase inhibitors have small positive effects on cognition in VaD, which are likely due to their action on co-existing AD-related neuropathology. Drug development efforts using novel approaches such as patient stratification by their genotype are needed in order to address the increasing need for effective VaD therapeutics.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
- Neuroprotection in vascular dementia.Martínez-Vila E, Murie-Fernández M, Gállego Pérez-Larraya J, Irimia P.Martínez-Vila E, et al.Cerebrovasc Dis. 2006;21 Suppl 2:106-17. doi: 10.1159/000091710. Epub 2006 May 2.Cerebrovasc Dis. 2006.PMID:16651821
- Galantamine: a review of its use in Alzheimer's disease and vascular dementia.Corey-Bloom J.Corey-Bloom J.Int J Clin Pract. 2003 Apr;57(3):219-23.Int J Clin Pract. 2003.PMID:12723727Review.
- Vascular dementia: distinguishing characteristics, treatment, and prevention.Román GC.Román GC.J Am Geriatr Soc. 2003 May;51(5 Suppl Dementia):S296-304. doi: 10.1046/j.1532-5415.5155.x.J Am Geriatr Soc. 2003.PMID:12801386Review.
- [Therapy of Alzheimer disease].Kovács T.Kovács T.Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33.Neuropsychopharmacol Hung. 2009.PMID:19731816Review.Hungarian.
- The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP.Alexopoulos GS, et al.Postgrad Med. 2005 Jan;Spec No:6-22.Postgrad Med. 2005.PMID:17203561
Cited by
- Icariside II Ameliorates Cognitive Impairments Induced by Chronic Cerebral Hypoperfusion by Inhibiting the Amyloidogenic Pathway: Involvement of BDNF/TrkB/CREB Signaling and Up-Regulation of PPARα and PPARγ in Rats.Yin C, Deng Y, Liu Y, Gao J, Yan L, Gong Q.Yin C, et al.Front Pharmacol. 2018 Oct 23;9:1211. doi: 10.3389/fphar.2018.01211. eCollection 2018.Front Pharmacol. 2018.PMID:30405422Free PMC article.
- 7, 8-dihydroxyflavone Ameliorates Cholinergic Dysfunction, Inflammation, Oxidative Stress, and Apoptosis in a Rat Model of Vascular Dementia.Dhaliwal N, Dhaliwal J, Chopra K.Dhaliwal N, et al.Neurochem Res. 2024 May;49(5):1137-1149. doi: 10.1007/s11064-023-04090-9. Epub 2024 Feb 1.Neurochem Res. 2024.PMID:38300457
- Large household reduces dementia mortality: A cross-sectional data analysis of 183 populations.You W, Henneberg M.You W, et al.PLoS One. 2022 Mar 3;17(3):e0263309. doi: 10.1371/journal.pone.0263309. eCollection 2022.PLoS One. 2022.PMID:35239673Free PMC article.
- Small vessel disease and memory loss: what the clinician needs to know to preserve patients' brain health.Schenk C, Wuerz T, Lerner AJ.Schenk C, et al.Curr Cardiol Rep. 2013 Dec;15(12):427. doi: 10.1007/s11886-013-0427-6.Curr Cardiol Rep. 2013.PMID:24105643Review.
- A Brief Review of Nutraceutical Ingredients in Gastrointestinal Disorders: Evidence and Suggestions.Gao X, Liu J, Li L, Liu W, Sun M.Gao X, et al.Int J Mol Sci. 2020 Mar 6;21(5):1822. doi: 10.3390/ijms21051822.Int J Mol Sci. 2020.PMID:32155799Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources